The company has yet to file a prospectus for the IPO. If the IPO goes according to plan, it could result in a valuation of $600 million for EndoChoice, according to the report.
More articles on gastroenterology:
To survive in GI, be prepared
Do gastroenterologists underestimate IBD severity?
15 gastroenterologists making headlines this month
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
